Transcript 3. - AIBL
The Australian Imaging Biomarkers and Lifestyle
Flagship Study of Ageing
.
(AUSTRALIAN ADNI)
July 2015 UPDATE
Christopher Rowe MD – Neuroimaging stream leader
AIBL commenced recruitment in October 2006.
Total Recruitment to Date = 1550.
Enrichment
follow-up
Inception
follow-up
397 NMC
619 SMC
234 MCI
291 AD
5 Non-AD
0m
361 NMC
499 SMC
139 MCI
246 AD
5 Non-AD
18m
311 NMC
348 SMC
66 MCI
170 AD
6 Non-AD
36m
261 NMC
299SMC
51 MCI
102 AD
5 Non-AD
54m
213 NMC
271 SMC
48 MCI
59 AD
7 Non-AD
72m
105 NMC
141 SMC
17 MCI
12 AD
4 Non-AD
90m
Person years
Years
NMC
SMC
MCI
AD
Non-AD
Total
1877
2337
483
884
41
5619
AIBL Highlights
AD Mean
Ab PET has defined the course of AD
Villemagne VL, et al. Lancet Neurology 2013
- diagnostic, prognostic and therapeutic implications
Detectable
Continually under refinement.
0
10
20
30 yrs
0.10
Aβ+ ε4-
-0.40
Genes and lifestyle
influences on decline
Lim YY et al.
Molecular Psychiatry 2014
GWAS and SNP
analyses underway.
-0.90
Aβ+ ε4+
BDNFVal/Va
-1.40
l
-1.90
Aβ+ ε4+
BDNFMet
-2.40
Baseline
18 month
36 month
54 month
4.5 year imaging data release
PiB Baseline (288), 3 years (173), 4.5 yrs (141)
Plus 230 more imaged with flutemetamol,
florbetapir or PiB at 3 or 4.5 yrs
Plus 245 new recruits (150 flute, 95 FBP)
(Ab status known in 371 subjects with 4.5 yrs of follow-up)
www.adni.loni.usc.edu
- Data and Samples
- Access Data
GAAIN Centiloid
Implemented the Centiloid transformation
for 11C-PiB and 18F-NAV4694
with 18F-Florbetapir to follow.
160
140
120
100
80
60
40
20
0
-20
0.5
1.0
1.5
2.0
2.5
GAAIN PiB SUVR
3.0
Tau Imaging
AV1451
THK5117 (now
replaced with
THK5351)
Beta-amyloid
Tau
THK5317 tau imaging in Alzheimer’s disease
tau
Braak & Braak
Stage V-VI
Ab
18F-THK5317
18F-FLUTEMETAMOL
MilxView
Braak & Braak
Stage C
18F-THK5351
PET
Normal 71 yr old.
MMSE 29.
Mild tau tracer retention
in anteromedial temporal
lobe but much less than
in AD
Negative
Ab PET
Ab PET +ve
69 yrs old female
with MCI
MMSE 24 CDR 0.5
Tau PET – right top and bottom
- 18F-THK5351
64 yrs with “AD”
but
Ab PET Negative
Memory -3 SD
Other domains OK
MMSE 28
CDR 1
THK5351 shows high
medial temporal tau
Screening for AD Drug Trials
Cumulative Stats: Dec '14- June '15
200
150
Referrals
100
FDG and amyloid PET if:
- MCI/mild AD (CVLT <-1 SD)
- trial suitable
- willing to go into a drug trial
Screens
50
Completers
e
Ju
n
M
ay
Ap
ril
M
ar
ch
ua
ry
Fe
br
ar
y
Ja
nu
De
ce
m
be
r
0
MCI/AD Referrals to June '15
200
150
100
50
0
Waiting
Excluded
Eligible
Total Ref
Total
Screens
To date 9/43 (20%) had negative Ab PET
Reports go to treating doctor.
That doctor chooses trial or asks
us to do this.
All scanned patients enrol in
AIBL
- more MCI/AD baseline data
- good source of Ab –ve MCI
and AD mimics - (20%)
A4 Trial in Australia
Over 1000 website registrations of interest
Ab PET screening commenced early 2015
50 screening PET to date
Aiming for 100 on study
AIBL-VETS
Tau and Beta-Amyloid Deposition, Micro
hemorrhage and Brain Function after Traumatic
Brain Injury in War Veterans
Award W81XWH-13-MRPRA-CSRA
Principal Investigator: Christopher Rowe MD
Future Directions for AIBL
• Further refine prognostic value and
comparative effectiveness of imaging and
blood biomarkers
• Examine genetic and environmental
influences on rate of decline in Ab+ve HC
• Serial tau imaging
• Create new pools of Ab +ve for early
intervention trials
• Use AIBL infrastructure to support more A4
and DIAN therapy type trials
ACKNOWLEDGEMENTS
AIBL study participants and their families
AIBL Study team
David Ames
Mary Barnes
Kevin Barnham
Shayne Bellingham
Sabine Bird
Julia Bomke
Pierrick Bourgeat
Sveltana Bozinovski
(nee Pejoska)
Belinda Brown
Rachel Buckley
Samantha Burnham
Ashley Bush
Pratishtha
Chatterjee
Lesley Cheng
Steven Collins
Ian Cooke
Kay Cox
Elizabeth Cyarto
David Darby
James Doecke
Vincent Dore
Denise El-Sheikh
Maree Farrow
Noel Faux
Michael Fenech
Shane Fernandez
Binosha Fernando
Christopher Fowler
Maxime Francois
Jurgen Fripp
Shaun Frost
Sam Gardener
Simon Gibson
Veer Gupta
David Hanson
Karra Harrington
Andy Hill
Eugene Hone
Maryam Hor
Malcolm Horne
Gareth Jones
Adrian Kamer
Yogi Kanagasingam
Neil Killeen
Hannah Korrel
Fiona Lamb
Nicola
Lautenschlager
Simon Laws
Wayne Leifert
Kate Lennon
Hugo Leroux
Qiao-Xin Li
Yen Ying Lim
Florence Lim
Lucy Lim
Linda Lockett
Andrea Louey
Kathy Lucas
Lance Macaulay
Lucy Mackintosh
Ralph Martins
Georgia Martins
Paul Maruff
Colin Masters
Simon McBride
Alissandra Mcilroy
AIBL is a large collaborative study and a complete list of
contributors can be found at www.aibl.csiro.au
Julie Nigro
Steve Pedrini
Kayla Perez
Kelly Pertile
Tenielle Porter
Stephanie RaineySmith
Carolina Restrepo
Malcolm Riley
Barbara Rita
Cardoso
Blaine Roberts
Jo Robertson
Mark Rodrigues
Christopher Rowe
Rebecca Rumble
Tim Ryan
Jack Sach
Olivier Salvado
Neil Saunders
Greg Savage
KaiKai Shen
Brendan Silbert
Harmid Sohrabi
Kevin Taddei
Tania Taddei
Sherilyn Tan
Christine Thai
Philip Thomas
Brett Trounson
Giuseppe Verdile
Victor Villemagne
Irene Volitakis
Michael Vovos
Larry Ward
Andrew Watt
Mike Weinborn
Rob Williams
Bill Wilson
Michael Woodward
Paul Yates
Fernanda Yevenes
Ugarte
Ping Zhang